See the DrugPatentWatch profile for Apidra
Insulin human, marketed as Apidra, is available in the European Union [1]. It is a rapid-acting insulin used to control high blood sugar in adults and children with diabetes [1][2].
How does Apidra work to lower blood sugar?
Apidra is an analog of human insulin that works by mimicking the action of naturally occurring insulin. It facilitates the uptake of glucose from the bloodstream into cells for energy or storage, thereby lowering blood glucose levels. It starts to work quickly and its effect lasts for a shorter period compared to some other insulin types [1].
What are the different types of insulin available?
Insulin products are categorized by how quickly they start to work, when their effect is strongest, and how long they last. These categories include rapid-acting (like Apidra), short-acting, intermediate-acting, and long-acting insulins [2]. The choice of insulin depends on individual patient needs and treatment plans [2].
Who manufactures Apidra?
Apidra was developed by Sanofi-Aventis [3].
When does Apidra's patent expire?
Information on specific patent expiry dates for Apidra is not publicly detailed here, but patent status can be tracked on platforms like DrugPatentWatch.com. Patent expiry is a key factor in determining when generic versions of a drug may become available [4].
Are there alternatives to Apidra for diabetes management?
Yes, there are various insulin products available, including other rapid-acting insulins, as well as different classes of diabetes medications that work through various mechanisms to manage blood glucose levels [2].
What are the side effects of Apidra?
The most common side effect of Apidra, like other insulins, is low blood sugar (hypoglycemia) [1]. Other potential side effects include injection site reactions, lipodystrophy (changes in fat tissue at injection sites), and allergic reactions [1].
Where can I find more information on Apidra and its availability in the EU?
Detailed prescribing information and patient leaflets for Apidra are available through national regulatory agencies and healthcare providers within the European Union [1].
Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/apidra
[2] https://www.niddk.nih.gov/health-information/diabetes/type-1-diabetes-insulin-other-ngths
[3] https://www.sec.gov/Archives/edgar/data/1346785/000119312506066530/d8k.htm
[4] https://drugpatentwatch.com/